Management of metastatic renal cell carcinomass

The management of metastatic renal cell carcinoma had changed over the last ten years with the apparition of new treatments and advances in surgery and ablative techniques. The therapies for metastatic patients have also been personalized and different prognostic groups have been established to adap...

Full description

Saved in:
Bibliographic Details
Published inProgrès en urologie (Paris) Vol. 28; no. 14; p. 777
Main Authors Rolley, C, Aubert, C, Baize, N, Bigot, P
Format Journal Article
LanguageFrench
Published France 01.11.2018
Subjects
Renal cell carcinoma
Targeted therapy
Immunotherapy
Surgery
Thérapie ciblée
Chirurgie
Cancer du rein
Metastasis
Métastatique
Immunothérapie
Online AccessGet more information

Cover

More Information
Summary:The management of metastatic renal cell carcinoma had changed over the last ten years with the apparition of new treatments and advances in surgery and ablative techniques. The therapies for metastatic patients have also been personalized and different prognostic groups have been established to adapt the treatment to the severity of the disease. Surgical excision, radiotherapy or ablative therapy could be proposed for patients with isolated metastasis and good condition to delay the systemic therapy initiation. Until 2006, in case of metastatic renal cell carcinoma, immunotherapy (IL-2 and TNF-alpha) was proposed. Targeted therapies acting on angiogenesis mechanisms have also been developed. Recently, immunotherapy has revolutionized the therapeutic management and has improved the overall survival of patients with metastatic renal carcinoma. For each patient, a multidisciplinary management is organized with a personal therapeutic project. This global management needs coordination with the medical team and also need a good communication with the patient, his entourage and his doctor.
ISSN:1166-7087
DOI:10.1016/j.purol.2018.07.280